Axsome Therapeutics (AXSM) Share-based Compensation (2015 - 2026)

Axsome Therapeutics has disclosed Share-based Compensation across 12 years of filings, most recently posting $23.4 million for Q1 2026.

• Share-based Compensation for Q1 2026 came in at $23.4 million, up 0.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $93.9 million (up 6.28% YoY), and the FY2025 annual result was $93.8 million, up 10.01% from the prior year.
• Share-based Compensation came in at $23.4 million for Q1 2026 at Axsome Therapeutics, up from $22.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $37.7 million in Q4 2022 to a low of $7598.0 in Q1 2022.
• The 5-year median for Share-based Compensation is $21.4 million (2024), against an average of $17.9 million.
• Across the five-year window, Share-based Compensation plunged 99.84% in 2022 and surged 177871.08% in 2023, its largest moves.
• Axsome Therapeutics' Share-based Compensation stood at $37.7 million in 2022, then slumped by 49.83% to $18.9 million in 2023, then grew by 16.24% to $22.0 million in 2024, then rose by 3.38% to $22.7 million in 2025, then grew by 3.11% to $23.4 million in 2026.
• The last three Share-based Compensation figures came in at $23.4 million (Q1 2026), $22.7 million (Q4 2025), and $23.1 million (Q3 2025), per Business Quant data.